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Introduction
Gingival overgrowth is a common side effect of the 
chronic use of the immunosuppressive drug, cy-
closporin A (CsA). The incidence of CsA-induced 
gingival overgrowth varies from 8% to 85% among 
studies, depending on the criteria used.1−3 CsA-
induced gingival overgrowth is characterized by 
thickening of the gingival epithelium as well as a 
marked increase in the extracellular matrix (ECM) 
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of the gingival connective tissue.4 Etiologic factors 
causing and underlying gingival overgrowth have 
been reviewed, and it was determined that local, 
systemic and genetic factors may contribute to its 
development and progression.5,6 Recently, our stud-
ies showed that upregulation of plasminogen acti-
vator inhibitor-17 and cystatin C8 may contribute 
to ECM accumulation in CsA-induced gingival over-
growth. However, the exact mechanism whereby 
CsA induces gingival overgrowth remains largely 
obscure.
Lysyl oxidase (LOX) is a secreted, copper-
dependent oxidase that deaminates the 3-amino 
group of lysines in collagen and elastin. The result-
ing aldehydes condense to form cross-linkages 
between collagen and elastin monomers.9,10 LOX 
catalyzes the oxidative deamination of lysine resi-
dues in elastin and collagens as an initial step in 
their extracellular assembly into insoluble fibers.11 
This has the effect of converting soluble monomers 
of collagen and elas tin into insoluble fibers in the 
ECM.12 Upregulation of LOX expression and increased 
LOX activity have been seen in a variety of fibrotic 
diseases such as liver fibrosis,9 scleroderma,13 renal 
fibrosis,14 and oral submucous fibrosis.15,16
Previously, LOX protein expression was detected 
in phenytoin-induced gingival overgrowth tissues.17 
The findings suggest that LOX may play an impor-
tant role in the pathogenesis of CsA-induced gingi-
val overgrowth. On the basis of these observations, 
the pres ent work was undertaken to identify the 
in situ localization of LOX expression in normal gin-
gival tissues and CsA-induced gingival overgrowth 
specimens.
Materials and methods
Tissue collection
Normal gingival tissue samples were obtained from 
five healthy individuals undergoing routine surgical 
crown lengthening with little, if any, evidence of in-
flammation and who were not receiving any systemic 
medication. Fifteen hyperplasic gingival biopsy 
specimens were obtained from 10 renal transplant 
patients receiving CsA therapy. These patients had 
been taking CsA for more than 1 year, and the dose 
had been adjusted to maintain stable serum levels 
of about 200 ng/mL. No sign of graft rejection was 
detected in these renal transplant patients. The 
samples were obtained during surgical removal of 
diseased gingival tissue as part of their routine clin-
ical management, which also included intensive 
plaque control. Institutional Review Board permis-
sion at Chung Shan Medical University Hospital was 
obtained for the use of discarded human tissue.
Immunohistochemistry
The surgically removed gingival tissues were fixed 
with 10% buffered formalin overnight, and the 
specimens were then dehydrated in an ascending 
series of graded alcohol and embedded in paraffin. 
Five-micrometer sections were stained with the 
monoclonal anti-LOX antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA; 1:100 dilution) 
using a standard avidin-biotin-peroxidase complex 
method.7,8 Diaminobenzidine (Zymed, South San 
Francisco, CA, USA) was then used as the substrate 
for localizing the antibody binding. Three biopsy 
specimens of oral submucous fibrosis were used as 
positive controls.16 Negative controls included se-
rial sections from which either the primary or sec-
ondary antibodies were excluded. The preparations 
were counterstained with hematoxylin, mounted 
with Permount (Merck, Darmstadt, Germany), and 
examined by light microscopy.
One section from each CsA-induced gingival 
overgrowth specimen was stained with hematoxy-
lin and eosin to evaluate the magnitude of inflam-
mation at the histologic level. Each specimen was 
graded at 200 × magnification as low (< 50% inflam-
matory cells per field) or high grade (> 50% inflam-
matory cells per field). Grading of each specimen 
was based on the average inflammatory condition in 
three consecutive microscopic fields, beginning from 
the epithelial-connective tissue border and proceed-
ing gradually deeper into the lamina propria.
After immunohistochemical processing for LOX 
expression, sections graded as low were represented 
by < 50% of positively stained cells, while sections 
graded as high exhibited > 50% positively stained 
cells on three sections per tissue at 400 × magnifi-
cation. The same fields were used to grade inflam-
mation and LOX staining.
Statistical analysis
Three replicates of each experiment were performed 
for each test. All assays were repeated three times 
to ensure reproducibility. Fisher’s exact test was 
used to test for differences in LOX between normal 
healthy gingival tissues and CsA-induced gingival 
overgrowth specimens.
Results
Fig. 1 shows gingival tissue obtained from the normal 
gingival group with faint LOX expression, which 
was almost totally limited to the epithelium and 
endothelium. In the CsA-induced gingival overgrowth 
group, intensive LOX expression was mainly observed 
in the cytoplasm of fibroblasts, epithelial cells and 
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inflammatory cells (Fig. 2). LOX staining of gingi-
val tissue was stronger in the CsA-induced gingival 
overgrowth group than in the normal gingival group 
(P < 0.05). The rank order of cells positively stained 
for LOX was found to be as follows: inflammatory 
cells (100%) > endothelial cells (93.3%) > fibroblasts 
(80%) > epithelial cells (60%).
LOX expression levels in CsA-induced gingival 
overgrowth specimens with either low or high lev-
els of inflammation are given in Table 1. Differences 
in LOX expression between tissues with low and 
high levels of inflammation were subsequently an-
alyzed using Fisher’s exact test. Significantly greater 
LOX expression was noted in CsA-induced gingival 
overgrowth tissues with high levels of inflamma-
tion (P = 0.017).
Oral submucosal fibrosis specimens were used 
as positive controls. As shown in Fig. 3, LOX stain-
ing was detected in fibroblasts and endothelial 
cells.
Discussion
Besides the fact that the increase in the ECM is not 
well understood in CsA-induced gingival over-
growth, there is no evidence for expression of LOX 
in this type of lesion. In oral fibrotic disorders, the 
expression of LOX was found to be significantly 
upregulated in oral submucosal fibrosis15,16 and 
phenytoin-induced gingival overgrowth tissues.17 It 
is reasonable to speculate that LOX may be directly 
related to the pathogenesis of CsA-induced gingival 
overgrowth.
LOX, an extracellular enzyme, plays a key role 
in the post-translational modification of collagens 
and elastin, catalyzing inter- and intra-crosslinking 
reactions.12 Because the crosslinked ECM is highly 
Fig. 1 Very faint immunoreactivity of lysyl oxidase was 
observed in normal human gingival tissues, and it was 
almost totally limited to the epithelium and endothe-
lium (original magnification ×400). The bar represents 
20 μm.
Fig. 2 Strong immunostaining for lysyl oxidase was noted 
in cyclosporin A-induced gingival overgrowth specimens. 
Lysyl oxidase was evident as an intense reddish-brown 
color in the cytoplasm of fibroblasts, epithelial cells, 
endothelial cells and inflammatory cells (original magni-
fication ×200). The bar represents 20 μm.
Table 1. Results of lysyl oxidase (LOX) expression and 
the grade of inflammation in cyclosporin A (CsA)-
induced gingival overgrowth tissues
 Level of inflammation
 High Low
LOX expression*
  Low 1 4
  High 8 2
*Significantly greater LOX expression was noted in CsA-induced 
gingival overgrowth tissues with high levels of inflammation 
compared with tissues with low levels of inflammatory cell 
infiltrates by Fisher’s exact test (P = 0.017).
Fig. 3 Photomicrograph showing staining by a peroxidase-
labeled streptavidin-biotin technique for lysyl oxidase in 
an oral submucosal fibrosis specimen which served as the 
positive control (original magnification ×400). The bar 
represents 20 μm.
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resistant to degradative enzymes, it is thought that 
overexpression of LOX may cause severe fibrotic 
degeneration. Many reports have clearly demon-
strated that LOX is consistently and dramatically 
upregulated in a variety of fibrotic diseases.9,13−17 
To the best of our knowledge, this is the first re-
port of LOX expression being upregulated in CsA-
induced gingival overgrowth specimens compared 
with normal gingival tissues. Strong immunostain-
ing for LOX was detected in fibroblasts, epithelial 
cells, and inflammatory cells. LOX deposition is as-
sociated with CsA-induced gingival overgrowth, sug-
gesting that it may play an important role in ECM 
turnover. From this phenomenon, we propose that 
CsA-induced gingival overgrowth may be due to 
the increased synthesis and deposition of ECM pro-
teins, their altered degradation, or both.
Many studies have suggested that plaque-induced 
inflammation is associated with the onset or sever-
ity of drug-induced overgrowth,18,19 and histologic 
findings have shown the presence of some level 
of inflammatory infiltrate in overgrown gingival 
tissues.7,8 Here, the expression of LOX increased 
with the grade of inflammation in CsA-induced gin-
gival overgrowth specimens. The LOX protein has 
consistently been found to be highly expressed in 
rat inflamed oral lesions in vivo, while normal non-
inflamed periapical tissue contained no LOX-positive 
cells.20 Our results suggest that CsA may predispose 
tissues to fibrosis via LOX overexpression in an in-
flammatory environment.
At present, no effective antifibrotic therapy is 
available that can be used for patients with CsA-
induced gingival overgrowth. β-Aminopropionitrile 
is an irreversible inhibitor of LOX,21 an extracellu-
lar enzyme that promotes crosslink formation 
in nascent fibrils of both collagen and elastin by 
conversion of lysine and hydroxylysine side chain 
residues into aldehydes. β-Aminopropionitrile was 
found to significantly decrease the collagen con-
tent in bleomycin-induced pulmonary fibrosis in 
rats.22,23 Based on experimental evidence, anti-LOX 
activity may be suitable as an antifibrotic therapeu-
tic target to prevent or delay CsA-induced gingival 
overgrowth.
As far as we know, this is the first attempt to 
evaluate the role of LOX expression in CsA-induced 
gingival overgrowth in vivo. We have demonstrated 
that LOX is elevated in CsA-induced gingival over-
growth compared with normal gingival tissues. LOX 
expression was significantly higher in CsA-induced 
gingival overgrowth specimens with higher levels 
of inflammatory infiltrates. CsA may predispose tis-
sues to gingival overgrowth in inflammatory envi-
ronments. More detailed in vitro and in vivo studies 
are needed to clarify the roles of LOX in CsA-induced 
gingival overgrowth in humans.
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